Ozempic vs Zepbound

Ozempic and Zepbound represent two different generations of incretin-based therapies with distinct approved uses. Ozempic (semaglutide) is a GLP-1 receptor agonist approved by the FDA for improving glycemic control in adults with type 2 diabetes. Zepbound (tirzepatide) is a dual GIP and GLP-1 receptor agonist approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Because these medications carry different FDA indications, a direct comparison should be considered in that context, and patients should discuss individual treatment goals with their healthcare provider.

In clinical trials, the weight-loss outcomes observed with each drug's respective class have differed. In the STEP 1 trial, semaglutide 2.4 mg (the dose used in Wegovy, higher than the maximum Ozempic dose) demonstrated approximately 14.9% mean body weight reduction over 68 weeks. In the SURMOUNT-1 trial, tirzepatide at its highest dose (15 mg) showed approximately 22.5% mean body weight reduction over 72 weeks. It is important to note that these figures come from separate trials with different patient populations, dosing regimens, and study designs, so direct numerical comparisons have significant limitations. The SURMOUNT-5 trial, which compared tirzepatide and semaglutide head-to-head, may provide more meaningful comparative data.

The two medications also differ in their mechanisms. Ozempic acts on the GLP-1 receptor alone, while Zepbound activates both GIP and GLP-1 receptors, which according to FDA prescribing information may contribute to its effects on appetite, caloric intake, and metabolic function. Zepbound also received FDA approval in 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial data. Both medications are administered as once-weekly subcutaneous injections. Common side effects for both include nausea, vomiting, diarrhea, and other gastrointestinal symptoms, particularly during dose escalation. Because these drugs serve different primary indications, the choice between them depends on the individual patient's diagnosis, treatment goals, insurance coverage, and prescriber recommendation.